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OL-048 Dynamic changes of CTLs, NK cells, and
NKT cells in patients with acute hepatitis B
infection
J. Li1 *, Y.P. Han1, K. Jin1, Y.F. Wan1. 1Department of
Infectious Diseases, China
Background: To explore the effects of speciﬁc CTLs, NK and
NKT cells on viral clearance and liver injury in patients with
self-limited AHB.
Methods: Dynamic proﬁles on the frequency of certain
MHC-Pentamer speciﬁc CTLs and lymphocyte subsets in AHB
patients were analyzed and their relationships to changes in
liver function, HBVM, and HBV DNA levels were examined.
ELISPOT was conducted to detect INF-g secretion of speciﬁc
CTLs.
Results: Frequencies of HBV-speciﬁc CTLs in AHB patients
were higher than in CHB patients. HBeAg and HBV DNA
disappeared earlier in AHB patients with a high frequency
of HBV-speciﬁc CTLs. INF-g spots were signiﬁcantly greater
in AHB patients. CD3+CD8+ cells in AHB patients was more
than that in healthy control and reached peak levels at
the second week after admission. NK and NKT cells were
signiﬁcantly lower in AHB patients and were negatively
correlated with the frequency of HBcAg-speciﬁc CTLs.
Conclusions: HBV-speciﬁc CTLs play an important role in
viral clearance and the self-limited process of the disease.
NK and NKT cells are likely involved in the early, non-speciﬁc
immune response to clear the virus that exists in the liver.
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In recent decades emerging infectious diseases and
expanding global travel have increased the risk of natural
and human-promulgated infections. The escalating risk
affects all nations and economies. One shared priority for
the global health community is the development of new
capabilities to meet the demand for abundant, inexpensive,
safe and effective vaccines for all nations. In the last
six years there are four examples where conventional
vaccine manufacturing using egg-based or mammalian cell-
produced whole virus inactivated vaccine systems failed
to meet the needs of Governments that were responding
to emerging health threats. Several countries in Africa
and Asia have lamented that pathogens procured under
international collaborations have been transitioned into
valuable vaccines for resource-rich nations without the
donor nation beneﬁting from access or recompense. One
response to these developments is a growing reluctance
of nations to openly share viruses or convalescent serum.
New strategies are therefore needed to ensure vaccine
security for all nations. At this time numerous novel protein
expression and subunit vaccine manufacturing technologies
are under development in Asia, Europe and North America.
A subset of these technologies have attributes which are
proven to reduce the cost and increase the availability of
safe and effective vaccines. This presentation will review
recent commercial and government accomplishments in the
development of vaccine manufacturing platforms developed
in both the East and West. The merits of each platform
in meeting WHO, EMEA and FDA regulatory approval, in
addressing the urgent timelines required for pandemic
response, and the ability to meet public health needs of
participating nations will be presented. The presentation
will focus in particular on proven subunit vaccine expression
technologies which forgo the proven “recombine-grow-kill-
and-ﬁll” strategies of cell and egg based systems, and
technologies which predict vaccine safety and efﬁcacy prior
to clinical trials.
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Objective: To evaluate the performs of the second stage
external quality assessment (EQA) relevant to laboratory
diagnoses of Anaplasmosis in 10 Provincial/City CDCs
laboratories in China.
Methods: The micro-indirect immunoﬂuoresce assay (mIFA)
proposed by WHO Rickettsial Diseases Collaborating Center
was assessed as a standard serological diagnoses technique.
The performances of two nested PCR assays, one testing
for most members of family Rickettsia by amplifying groEL
gene and the other targeting members of family Anaplasm
by amplifying 16SrRNA gene, were evaluated. Participants
received a package containing primers and 5 reference
templates (P1, P2, P3, P4, P5) for PCR tests, and S1 and
S2 reference sera for serological assays. Each laboratory
was asked to perform these procedures by using their
own laboratory condition including equipments and some
reagents except the provided reference materials.
Results: 7 laboratories from 10 participants units returned
their results for testing S1 and S2 references, and among
these 7 Labs, 5 (71.4%) were eligible according to
the assessment criteria. 8 participated laboratories gave
their PCR results and there are signiﬁcant differences
in speciﬁcity and sensitivity of PCR performance among
laboratories, with 62.5% (5/8) of laboratories providing
acceptable results for P1 and P2 PCR references and
50% (5/10) of laboratories deﬁning eligible results for P4, P5,
P6 references. For repeatability evaluation, all laboratories
reported acceptable results.
Conclusion: Each participated laboratory had systematic
error in their performances. Revising these errors should be
performed and internal quality control for these techniques
should be conducted regularly in future surveillance works.
Supported by the national basic research project-
973 plan (2010CB530206), and special project of
key communicable viral hepatitis-research on infectious
diseases surveillance platform of national Sci-Tech key
